Cargando…

Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study

BACKGROUND: Pharmacogenetics (PGx), especially in regard to CYP2D6, is gaining more importance in routine clinical settings. Including phenoconversion effects (PC) in result interpretation could maximize its potential benefits. However, studies on genetics of pharmacokinetic genes including the func...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scherf-Clavel, Maike, Frantz, Amelie, Eckert, Andreas, Weber, Heike, Unterecker, Stefan, Deckert, Jürgen, Reif, Andreas, Hahn, Martina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600053/ https://www.ncbi.nlm.nih.gov/pubmed/37166747 http://dx.doi.org/10.1007/s11096-023-01588-8

Ejemplares similares

Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age
por: Hommers, Leif, et al.
Publicado: (2021)

Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response
por: Scherf-Clavel, Maike, et al.
Publicado: (2022)

Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients
por: den Uil, Manon G., et al.
Publicado: (2023)

Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions
por: Unterecker, Stefan, et al.
Publicado: (2014)

Patients with higher vitamin D levels show stronger improvement of self-reported depressive symptoms in psychogeriatric day-care setting
por: Zech, Linda D., et al.
Publicado: (2021)

The impact of CYP2C19 genotype on phenoconversion by concomitant medication
por: de Jong, Laura M., et al.
Publicado: (2023)

Serious Adverse Drug Reactions in Children and Adolescents Treated On- and Off-Label with Antidepressants and Antipsychotics in Clinical Practice
por: Egberts, Karin M., et al.
Publicado: (2022)

Pharmacogenetic CYP2D6 variability, phenoconversion and treatment outcomes: A Danish population-based cohort study in 6,798 individuals initiating atomoxetine treatment
por: Ishtiak-Ahmed, K., et al.
Publicado: (2022)

Pharmacogenetics of Antidepressants
por: Crisafulli, Concetta, et al.
Publicado: (2011)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

In Silico Pharmacogenetics CYP2D6 Study Focused on the Pharmacovigilance of Herbal Antidepressants
por: Don, Charleen G., et al.
Publicado: (2020)

Pharmacogenetics and outcome with antipsychotic drugs
por: Pouget, Jennie G., et al.
Publicado: (2014)

Pharmacogenetics of antidepressant response: An update
por: Drago, Antonio, et al.
Publicado: (2009)

Phenoconversion from Spastic Paraplegia to ALS/FTD Associated with CYP7B1 Compound Heterozygous Mutations
por: Theuriet, Julian, et al.
Publicado: (2021)

Pharmacogenetics of antipsychotic-induced side effects
por: Lencz, Todd, et al.
Publicado: (2009)

The Pharmacogenetics of Symptom Response to Antipsychotic Drugs
por: Reynolds, Gavin P
Publicado: (2012)

EXPERIENCE OF PHARMACOGENETIC TESTING IN THE TREATMENT OF ANTIPSYCHOTICS
por: Kaydan, M., et al.
Publicado: (2023)

The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics
por: Giorgetti, Arianna, et al.
Publicado: (2023)

Insights from pharmacogenetic studies of antidepressants
por: Mandelli, Laura
Publicado: (2010)

Optimization of Antidepressant use with Pharmacogenetic Strategies
por: Torrellas, Clara, et al.
Publicado: (2017)

Dasatinib-induced nephrotic syndrome: a case of phenoconversion?
por: Mandac Rogulj, Inga, et al.
Publicado: (2019)

Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion
por: Gharaee-Kermani, Mehrnaz, et al.
Publicado: (2016)

Cardiovascular Risk Factors and Phenoconversion to Neurodegenerative Synucleinopathies in Idiopathic REM Sleep Behavior Disorder
por: Zolfaghari, Sheida, et al.
Publicado: (2022)

The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy
por: Radosavljevic, Milica, et al.
Publicado: (2023)

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism
por: Deodhar, Malavika, et al.
Publicado: (2021)

CXC-Type Chemokines Promote Myofibroblast Phenoconversion and Prostatic Fibrosis
por: Gharaee-Kermani, Mehrnaz, et al.
Publicado: (2012)

The role of club cell phenoconversion and migration in idiopathic pulmonary fibrosis
por: Fukumoto, Jutaro, et al.
Publicado: (2016)

Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review
por: Klomp, Sylvia D., et al.
Publicado: (2020)

Cardiosomal microRNAs Are Essential in Post-Infarction Myofibroblast Phenoconversion
por: Morelli, Marco B., et al.
Publicado: (2019)

Sleep Disturbances and Phenoconversion in Patients with REM Sleep Behavior Disorder
por: Jo, Hyunjin, et al.
Publicado: (2021)

Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations
por: Eum, Seenae, et al.
Publicado: (2016)

Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
por: Boloc, Daniel, et al.
Publicado: (2018)

The Potential for Kratom as an Antidepressant and Antipsychotic
por: Johnson, Lindsay E., et al.
Publicado: (2020)

Antidepressants- and antipsychotics-induced hepatotoxicity
por: Todorović Vukotić, Nevena, et al.
Publicado: (2021)

The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics
por: Austin-Zimmerman, Isabelle, et al.
Publicado: (2021)

Validation of the REM behaviour disorder phenoconversion-related pattern in an independent cohort
por: Orso, Beatrice, et al.
Publicado: (2023)

A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments
por: Arranz, Maria J., et al.
Publicado: (2019)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

An overview of QTc Prolongation with antipsychotics and antidepressants
por: Bhandari, Samrat Singh, et al.
Publicado: (2022)

Predictors of successful discontinuation of antipsychotics and antidepressants
por: Lincoln, Tania M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6pri5tpt3r4ktuijbjv7a7vr3f